Company Overview and News

4
Aflac's U.S. and Japan Business Poised for Strong Growth

2018-09-25 zacks
Aflac Inc. (AFL - Free Report) looks well poised for growth on the back of its strong Japan and U.S. business.
AFW AFGE AFA AFGH ACGL BRK.A AFG AFL 8686 AFSD ARHPF

 
Unum Group (UNM) Looks Good: Stock Adds 5.7% in Session

2018-09-19 zacks
Unum Group (UNM - Free Report) was a big mover last session, as the company saw its shares rise nearly 6% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $35.14 to $37.41 in the past one-month time frame.
UNM AFL 8686 AFSD

17
Zacks.com highlights: Huntsman, Covenant Transportation Group, ON Semiconductor, Rayonier Advanced Materials and Aflac

2018-09-18 zacks
Chicago, IL – September 18, 2018 - Stocks in this week’s article include: Huntsman Corp. (HUN - Free Report) , Covenant Transportation Group, Inc. (CVTI - Free Report) , ON Semiconductor Corp. (ON - Free Report) , Rayonier Advanced Materials Inc. (RYAM - Free Report) and Aflac Inc. (AFL - Free Report) .
RYAM CVGI GFN GFNCP VTNR MDP CVS CVTI ON JOUT GFNSL HUN GTES AFL MDPEB HEAR 8686 GFDV AFSD

2
5 Value Stocks With Exciting EV/EBITDA Ratios to Own Now

2018-09-17 zacks
Value investors generally tend to cling to the price-to-earnings (P/E) strategy while looking for stocks that are trading at a bargain. Undoubtedly, P/E is the most popular multiple used by investors for evaluating the fair market value of a stock. But even this straightforward, broadly used valuation metric is not without its shortcomings. EV/EBITDA is a Better Approach, Here’s Why While P/E enjoys great popularity, a less-used and more-complicated metric called EV/EBITDA gains an upper hand as it offers a clearer picture of a company’s valuation and earnings potential.
RYAM HUN AFL 8686 AFSD CVTI ON

2
MoneyGram Expands Services in Mexico With OXXO Stores Tie-Up

2018-09-12 zacks
MoneyGram International Inc. (MGI - Free Report) customers residing in Mexico now will be able to avail the facility of receiving money sent to them from across the world from thousands of new locations. The facilities of the leading global provider of money transfer and payment services are now available at around 17,000 OXXO convenience stores in Mexico. Consumers can pick up to 2,000 pesos in cash at the stores.
MGI ONDK AFL 8686 AFSD PRA

36
Euronet's Unit Signs Agreement for Better Money Transfer

2018-09-12 zacks
Euronet Worldwide, Inc.’s (EEFT - Free Report) subsidiary, Ria Money Transfer, recently announced its agreement with Boost Mobile, a unit of Sprint Corporation. Notably, the deal will enable Dealers of the Boost Mobile to provide domestic as well as international money transfer services. The agreement would further allow the customers to avail bill payment services at more than 6,000 locations globally.
ONDK AFL S EEFT 8686 AFSD PRA

18
Wall Street Looks Stunning: A Bumpy Road Ahead?

2018-09-04 zacks
Although the domestic market looks stunning now with the Wall Street extending its marathon run and corporate profits consistently rising, are there threats ahead?
JBK DISH CATR GSC CAT INPAP TFG GSJ GS GLSSP AFL IP 8686 AFSD GJS

7
Should First Trust Capital Strength ETF (FTCS) Be on Your Investing Radar?

2018-08-30 zacks
The First Trust Capital Strength ETF (FTCS - Free Report) was launched on 07/06/2006, and is a passively managed exchange traded fund designed to offer broad exposure to the Large Cap Blend segment of the US equity market.
IVV PFZ AFL AAPL NVMI 8686 IVV AFSD 500680 PFE PFIZER SMG

 
167-Year-Old MassMutual Adds New Online Startup With Quilt Deal - Bloomberg

2018-08-08 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
AFL 8686 AFSD

 
Should First Trust Capital Strength ETF (FTCS) Be on Your Investing Radar?

2018-08-06 zacks
Designed to provide broad exposure to the Large Cap Blend segment of the US equity market, the First Trust Capital Strength ETF (FTCS - Free Report) is a passively managed exchange traded fund launched on 07/06/2006.
IVV AFL 8686 IVV VLO AFSD BGSF FUN ROK

9
American International (AIG) Q2 Earnings Miss Estimates

2018-08-03 zacks
American International Group Inc. (AIG - Free Report) reported second-quarter 2018 operating earnings of $1.05 per share, missing the Zacks Consensus Estimate by 11.8%. Also, in the year-ago quarter, the company’s bottom line came in at $1.53.
TMK AVF TMK AIG AFL 8686 AFSD GNW 8685

8
Lincoln's (LNC) Q2 Earnings Miss Estimates, Increase Y/Y

2018-08-02 zacks
Lincoln National Corporation’s (LNC - Free Report) second-quarter 2018 earnings of $2.02 per share missed the Zacks Consensus Estimate by 3.8%. However, the bottom line improved about 9.2% year over year, mainly led by solid performances across all segments, annuity sales and the recent acquisition of Liberty.
TMK LNC AFL 8686 ENR AFSD GNW TMK

4
Unum Group (UNM) Q2 Earnings Beat Estimates, Revenues Miss

2018-08-01 zacks
Unum Group’s (UNM - Free Report) second-quarter 2018 operating net income of $1.30 per share beat the Zacks Consensus Estimate by 2.4%. Moreover, the bottom line improved 20.3% year over year on higher premiums and a stable benefits experience. Moreover, lower tax rate provided an additional boost to the metric.
UNM EIG BRK.A TMK AFL 8686 AFSD TMK

3
Aflac (AFL) Q2 Earnings Surpass Estimates, Revenues Miss

2018-07-27 zacks - 1
Aflac Inc.’s (AFL - Free Report) second-quarter 2018 earnings of $1.07 per share surpassed the Zacks Consensus Estimate by 9.2% and increased 15.2% year over year. Results buoyed up on overall favorable pretax margins and a lower effective tax rate as a result of tax reform.
EA AFL PGR NVR 8686 AFSD MTG TRN RLI

4
Insurance Stocks' Earnings Due on Jul 26: CINF, HIG & More

2018-07-25 zacks
The second-quarter earnings season is gathering momentum. Already, 87 members of the elite S&P 500 index have reported their financial numbers. Per the latest Earnings Preview, the performance of these index participants indicates 20.9% increase in total earnings on 10.3% higher revenues. The beat ratio is impressive, with 86.2% companies surpassing bottom-line expectations and 77% outperforming on the top-line front.
DB MMC AFL HIG CINF 8686 MS AFSD HGH CIT

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...